Grifols, S.A. (GRFS) P/E Ratio History
Historical price-to-earnings valuation from 2011 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of March 2, 2026, Grifols, S.A. (GRFS) trades at a price-to-earnings ratio of 33.5x, with a stock price of $9.10 and trailing twelve-month earnings per share of $0.55.
The current P/E is 51% above its 5-year average of 22.3x. Over the past five years, GRFS's P/E has ranged from a low of 11.3x to a high of 42.6x, placing the current valuation at the 95th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, GRFS trades at a 42% premium to its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
Relative to the broader market, GRFS commands a significant premium over the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our GRFS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Vaccines and plasma-derived therapies peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
MRKMerck & Co., Inc. | $307B | 17.0 | 0.80Best | +8% |
PFEPfizer Inc. | $157B | 20.3 | - | -4% |
GSKGSK plc | $119B | 16.2Lowest | - | +119% |
SNYSanofi | $118B | 20.3 | - | -7% |
GRFSGrifols, S.A. | $2B | 33.5 | - | +156%Best |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q3 | $9.96 | $0.55 | 18.2x | -32% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $9.04 | $0.43 | 20.8x | -22% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $7.11 | $0.28 | 25.0x | -7% |
| FY2024 Q4 | $7.44 | $0.23 | 32.9x | +23% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $8.88 | $0.21 | 42.6x | +59% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $6.31 | $0.22 | 28.6x | +7% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $6.68 | $0.40 | 16.7x | -38% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $11.56 | $0.56 | 20.6x | -23% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $9.14 | $0.81 | 11.3x | -58% |
| FY2021 Q2 | Wed Jun 30 2021 00:00:00 GM | $17.35 | $1.14 | 15.2x | -43% |
| FY2021 Q1 | Wed Mar 31 2021 00:00:00 GM | $17.29 | $0.99 | 17.5x | -35% |
| FY2020 Q4 | $18.44 | $1.08 | 17.1x | -36% |
Average P/E for displayed period: 26.8x
See GRFS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GRFS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare GRFS vs AGIO
See how GRFS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is GRFS stock overvalued or undervalued?
GRFS trades at 33.5x P/E, above its 5-year average of 22.3x. The 95th percentile ranking indicates a premium to historical valuation.
How does GRFS's valuation compare to peers?
Grifols, S.A. P/E of 33.5x compares to sector median of 23.7x. The premium reflects expected growth above peers.
What is GRFS's PEG ratio?
GRFS PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2011-2025.